Publications

According to PubMed MRV researchers have published >440 melanoma papers since 2010 and MRV has contributed to more than 195 publications.
Below is a snapshot of some recent MRV publications, highlighting the breadth of research disciplines that can utilise MRV’s data and biospecimens:

• 2017, Melanoma Staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual.CA: a cancer journal for clinicians. 2017 nov;67(6):472-492. Doi: 10.3322/caac.21409
• Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). J Immunother Cancer. 2021 Oct;9(10):e002995. doi: 10.1136/jitc-2021-002995. PMID: 34625515; PMCID: PMC8504361.
• Parakh S, Musafer A, Paessler S, Witkowski T, Suen CSNLW, Tutuka CSA, Carlino MS, Menzies AM, Scolyer RA, Cebon J, Dobrovic A, Long GV, Klein O, Behren A. PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Front Immunol. 2021 Jun 9;12:672521. doi: 10.3389/fimmu.2021.672521. PMID: 34177913; PMCID: PMC8220213.
• Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, Bastian B, Scolyer R, Waddell N, Penington A, Shackleton M. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. JAMA Dermatol. 2021 Jul 1;157(7):836-841. doi: 10.1001/jamadermatol.2021.0025. PMID: 34076666; PMCID: PMC8173474.
• Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, Mann GB, McArthur G, Solomon BJ, IJzerman MJ. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. Asia Pac J Clin Oncol. 2021 Aug;17(4):359-367. doi: 10.1111/ajco.13505. Epub 2021 Feb 10. PMID: 33567163; PMCID: PMC8014813.

A recent authorship review also identified a steady upward trend of collaboration between MRV partner sites. The results are graphed below.

For researchers using MRV resources

Please note: All researchers using MRV resources are formally obliged to acknowledge MRV in all related presentations and publications.

The MRV Acknowledgment for Papers and Presentations must read:

The authors wish to thank Melanoma Research Victoria and acknowledge the MRV sites contributing to this work: (select one or more)

• Peter MacCallum Cancer Centre,
• Victorian Melanoma Service, Alfred Health
• Olivia Newton-John Cancer Research Institute, Austin Health
• Skin Health Institute
• Border Medical Oncology Research Unit

OR

If Melanoma Research Victoria is listed as an author the following statement is included in the acknowledgements or supplementary note area –
The MRV Principal Investigators for this project are: (select one or more) Grant McArthur, Victoria Mar, Damien Kee, Peter Foley and Craig Underhill